ArcherDX
General Information | |
Business: |
We are a leading genomics company democratizing precision oncology. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. This empowers clinicians to control the sample, data, patient care and economics. Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development. We believe these benefits will drive broader adoption of precision oncology throughout the therapeutic continuum, improving patient care. Our product development platform, with our proprietary Anchored Multiplex PCR, or AMP, chemistry at the core, has enabled us to develop industry-leading products and services that optimize therapy and monitor cancer. |
Industry: | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
Employees: | 337 |
Founded: | 2013 |
Contact Information | |
Address | 2477 55th Street, Suite 202, Boulder, CO 80301, US |
Phone Number | (877) 771-1093 |
Web Address | http://www.archerdx.com |
View Prospectus: | ArcherDX |
Financial Information | |
Market Cap | |
Revenues | $55.9 mil (last 12 months) |
Net Income | $-54.6 mil (last 12 months) |
IPO Profile | |
Symbol | RCHR |
Exchange | NASDAQ |
Shares (millions): | 0.0 |
Price range | $0.00 - $0.00 |
Est. $ Volume | $100.0 mil |
Manager / Joint Managers | J.P. Morgan/ BofA Securities |
CO-Managers | Stifel/ Evercore |
Expected To Trade: | |
Status: | Withdrawn |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |